Reviewed by MedNext Clinical Team
Ibuprofen is a non-selective non-steroidal anti-inflammatory drug (NSAID) and one of the most widely used analgesics globally, available without prescription in most countries. Its anti-inflammatory, analgesic, and antipyretic properties make it valuable for a broad range of conditions. However, its risk profile — gastrointestinal, cardiovascular, and renal — means that safe use requires awareness of when it should be avoided or used with caution [1].
Mechanism and Therapeutic Uses
Ibuprofen inhibits both COX-1 and COX-2 enzymes, reducing prostaglandin synthesis at sites of inflammation and in the central nervous system. This accounts for its analgesic efficacy in musculoskeletal pain, dysmenorrhoea, headache, dental pain, and fever. At standard OTC doses (200–400 mg), its anti-inflammatory effect is modest; higher prescription doses (400–800 mg three times daily) are required for inflammatory conditions such as rheumatoid arthritis or acute gout.
Gastrointestinal Risk
COX-1 inhibition by ibuprofen reduces synthesis of cytoprotective prostaglandins in the gastric mucosa, impairing the mucous barrier and increasing susceptibility to acid injury. This produces a spectrum of GI harm from dyspepsia and gastritis to peptic ulceration and GI haemorrhage. A large meta-analysis involving over 750,000 patients confirmed that ibuprofen significantly increases the risk of upper GI complications compared to placebo, though its GI risk is lower than that of naproxen or indomethacin [1].
Gastroprotection with a proton pump inhibitor (PPI) should be co-prescribed in patients with additional GI risk factors: age over 65, prior peptic ulceration, concomitant anticoagulant or corticosteroid use, or high-dose NSAID therapy.
Cardiovascular Risk
All non-selective NSAIDs carry a cardiovascular risk through COX-2 inhibition, which reduces vasodilatory prostacyclin (PGI2) while preserving pro-thrombotic thromboxane A2. Ibuprofen carries a moderate cardiovascular risk compared to other NSAIDs, but should be avoided in patients with established ischaemic heart disease, cerebrovascular disease, peripheral arterial disease, or heart failure [1]. Where analgesia is needed in cardiovascular patients, paracetamol is the preferred first-line agent.
Renal Effects
Prostaglandins maintain renal perfusion in states of reduced effective circulating volume. Ibuprofen-induced prostaglandin inhibition can precipitate acute kidney injury in patients with heart failure, hypovolaemia, CKD, or cirrhosis. The combination of ibuprofen with ACE inhibitors (or ARBs) and diuretics — the "triple whammy" — significantly amplifies AKI risk and should be avoided. Ibuprofen should not be used in patients with eGFR below 30 mL/min/1.73m².
Key Contraindications
Ibuprofen should be avoided in: active peptic ulceration; severe heart failure; established cardiovascular disease (unless no alternative); CKD with eGFR below 30; third trimester of pregnancy (risk of premature closure of ductus arteriosus and oligohydramnios); and in patients already taking anticoagulants without gastroprotection. It should be used with caution in the first and second trimesters of pregnancy and in elderly patients, starting at the lowest effective dose for the shortest duration [1].
Alternatives to Consider
Where ibuprofen is contraindicated or high-risk, paracetamol offers effective analgesia without GI or cardiovascular risk for most patients. Topical NSAIDs (e.g., topical diclofenac gel) deliver anti-inflammatory effects locally with substantially lower systemic absorption and risk. For inflammatory conditions where systemic NSAIDs are required, risk stratification and co-prescribing of gastroprotection should be routine practice.
References
- Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-779.